Overland ADCT BioPharma

Overland ADCT BioPharma is a strategic joint venture formed by Overland Pharmaceuticals and ADC Therapeutics to develop and commercialize advanced antibody-drug conjugates (ADCs) in Greater China and Singapore. The company's lead asset, Zynlonta (loncastuximab tesirine), is a CD19-targeted ADC that has received conditional approval in China for the treatment of relapsed or refractory diffuse large B-cell lymphoma. By leveraging ADC Therapeutics' proprietary pyrrolobenzodiazepine (PBD) cytotoxic payload technology, the company aims to provide potent new treatment options for patients with hematologic malignancies and solid tumors. The joint venture's pipeline includes several clinical-stage candidates, such as ADCT-602 targeting CD22 and ADCT-601 targeting AXL. Overland ADCT BioPharma combines the innovative ADC platform of its Swiss partner with Overland's deep expertise in regional clinical development and commercialization. The company is headquartered in Shanghai and focuses on addressing significant unmet medical needs within the Asian oncology market.